Promise Grants

Promise Grants are organized around a critical issue or question that is being addressed by a set of closely-related clinical and laboratory projects designed to achieve significant results not attainable by investigators working independently. These grants differ significantly from Komen’s Investigator-Initiated Research (IIR) Grants. While the IIR Grants support one or two principal investigators to test a single hypothesis through one or more related research studies, utilizing either laboratory, clinical or public health approaches, Promise Grants are intended support two or three principal investigators and an investigative team that brings together and integrates laboratory, clinical and/or public health disciplines to conduct several related projects, the results of which converge to answer critical questions. Research projects supported by Promise Grants must provide an integrated approach to solving a critical challenge that will lead to the rapid translation of scientific discoveries into new or enhanced clinical tools and applications with the greatest potential to significantly reduce breast cancer incidence and/or mortality within the next decade. Projects must be designed to yield converging evidence that answers an important over-arching problem in breast cancer (e.g., resistance to currently available targeted therapies or novel therapies for triple negative breast cancer). Relevant research applications may include components that focus on breast cancer biology; genetics; epidemiology; prevention; detection; risk assessment; biomarkers of risk, disease burden, and/or treatment response or resistance; novel therapeutics; lifestyle interventions with the potential to affect disease outcomes (e.g., incidence and/or mortality); and novel approaches that enhance understanding of the breast cancer disease process.

Headquarters
5005 LBJ Freeway, Suite 250
Dallas, TX 75244

1-877 GO KOMEN